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Abstract
Background: To investigate a possible role of Cefditoren, a recently marketed in Greece third-generation oral
cephalosporin in urinary infections of outpatients.
Methods: During a multicenter survey of Enterobacteriaceae causing UTIs in outpatients during 2005–2007,
Cefditoren MICs were determined by agar dilution method in a randomly selected sample of uropathogens.
Susceptibility against 18 other oral/parenteral antimicrobials was determined according to Clinical and Laboratory
Standards Institute methodology.
Results: A total of 563 isolates (330 Escherichia coli, 142 Proteus mirabilis and 91 Klebsiella spp) was studied; MIC50/
MIC90 of Cefditoren was 0.25/0.5 mg/L respectively, with 97.1% of the isolates being inhibited at 1 mg/L. All 12
strains producing ESBLs or AmpC enzymes were resistant to cefditoren. Susceptibility rates (%) for amoxicillin/
clavulanic acid, cefuroxime axetil, cefotaxime, ciprofloxacin, trimethoprim/sulfamethoxazole and fosfomycin were
93.1- 94.1- 96.8-93.1-71.9 and 92.8% respectively. Cefditoren MIC was significantly higher in nalidixic/ciprofloxacin
non-susceptible strains; resistance to cefditoren was not associated with resistance to mecillinam, fosfomycin
nitrofurantoin and aminoglycosides. Multivariate analysis demonstrated history of urinary infection in the last two
weeks or three months as risk factors for cefditoren resistance.
Conclusions: Cefditoren exhibited enhanced in vitro activity against the most common uropathogens in the
outpatient setting, representing an alternative oral treatment option in patients with risk factors for resistance to
first-line antibiotics.
Keywords: Urinary tract infections, Acute uncomplicated cystitis, Cephalosporins, Antimicrobial resistance, Empirical
treatment
Background
Urinary tract infections (UTIs) represent the most fre-
quent bacterial infection encountered in the community
setting being caused in their vast majority by members
of the family of Enterobacteriaceae [1,2]. Recently, anti-
microbial resistance among uropathogens causing un-
complicated cystitis has increased, as well as the
recognition of the importance of the ecological adverse
effects of antimicrobial therapy (collateral damage) [2-6].
Effective empirical therapy must be based on susceptibil-
ity profiles of the uropathogens, therefore surveillance
studies are important tools to guide antibiotic selection
[3]. However, in a “real-life” scenario, empirical therapy
is most likely to be prescribed either without a urine cul-
ture or before the results become available. A recognized
drawback of many published studies is the inclusion of
strains collected from hospitals, thus limiting surveil-
lance in populations with easy access to tertiary centers
even as outpatients. Additionally, in several laboratory-
based studies no distinction could be safely made be-
tween complicated and uncomplicated UTIs; that same
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is true for purely “community” infections and nosoco-
mial or healthcare-associated infections that are being
treated in the community [3,6].
Cefditoren is a third generation oral cephalosporin with
a broad spectrum of activity comprising Gram-positive
and Gram-negative bacterial species [7,8]. After an oral
400-mg single dose, the mean concentrations in urine are
186.5 mg/L at 2 to 4 h and 12.7 mg/L at 8 to 12 h; available
data have shown its potential to be used in the treatment
of UTIs [9]. Cefditoren retained activity against some
clinically significant pathogens harboring β-lactamase
enzymes. In a study by Sevillano et al., cefditoren exhib-
ited bactericidal activity (>4 log10 reduction) against
TEM-1 (penicillinase production or hyperproduction) and
TEM-34 derivative (IRT-6) isolates from 4 to 24 h. How-
ever, against ESBL-producing strains, no sustained bacteri-
cidal activity was demonstrated: against strains harboring
the SHV determinant bactericidal activity was achieved
only in the 6- to 8-h whereas against the TEM-116 strain
a 2-log10 regrowth occurred from 12 to 24 h [9].
The present study was conducted in order to investi-
gate a possible role of cefditoren in the treatment of
UTIs treated in the outpatient setting. Given the
expanded spectrum of cefditoren, strains of uncompli-
cated as well as complicated UTIs were included.
Methods
Study period and participating institutions
From January 2005 to March 2007 a Greek multicentre
surveillance network was formed by private or public
microbiology laboratories, representative of the whole
country, in order to obtain Enterobacteriaceae isolates
from outpatients with UTI. Personal data were collected
anonymously. The research protocol was approved by the
Ethics Committees of the cooperating hospitals, namely
“Attikon” University General Hospital of Athens, “Sisma-
noglion”General Hospital of Athens and “G. Gennimatas”
General Hospital of Athens. Primary care centers and
Private Institutions participating in this study do not
have Ethics Committees. Isolated strains were shipped
to the central laboratory (Laboratory for Infectious
Diseases and Antimicrobial Chemotherapy, 4th Dept
of Internal Medicine, Athens University School of
Medicine, University General Hospital ATTIKON). The
network’s structure and methodology have been reported
previously [10].
Bacterial isolates
A single urine culture per outpatient referred for a urine
sample culture to each collaborating centre was collected
along with a detailed questionnaire tracking demographic
and clinical information. Clinical data included: reason
for giving a urine sample, symptoms, history of UTI (in
the last 2 weeks, 3 months or in the previous year prior
to sampling), recent use of antibiotics (in the previous
2 weeks and 3 months), history of admission to the hos-
pital and/or insertion of a urinary catheter during the
previous year, presence of diabetes mellitus, nephrolithia-
sis, presence of urinary catheter and pregnancy on sam-
pling [10]. A culture was considered positive with a
growth of a single microorganism >104 CFU/ml. Bacter-
ial isolates were identified by biochemical profiling using
API systems (BioMerieux, Basingstoke, UK).
Isolates included in the current study were randomly
selected from the total collection, which included 2446
microorganisms, 2280 of them being either E. coli, or
Proteus mirabilis or Klebsiella spp. As defined by the
study protocol every fourth isolate per center was
selected for the cefditoren study; 7 isolates were dropped
out due to contamination.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing to all antibiotics ex-
cept Cefditoren was performed using the disk diffusion
method, according to the Clinical Laboratory Standard
Institute recommendations, CLSI 2011 [11]. Antimicro-
bials tested (disks) were: Ampicillin (10 μg), Cephalothin
(30 μg), Cefuroxime (30 μg), Cefotaxime (30 μg), Cefta-
zidime (30 μg), Amoxicillin/Clavulanic acid (20/10 μg),
Piperacillin/tazobactam (100/10 μg), Ticarcillin/clavula-
nate (75/10 μg), Imipenem (10 μg), Ciprofloxacin (5 μg),
Trimethoprim/Sulfamethoxazole (1.25/23.75 μg), Nali-
dixic acid (30 μg), Nitrofurantoin (300 μg), Fosfomycin
(200 μg), Mecillinam (10 μg), Gentamicin (10 μg), Ami-
kacin (30 μg), Netilmicin (30 μg). Additionally, in view
of the widespread use of quinolones in our community,
MICs for Ciprofloxacin were determined by E-test
method (AB-Biodisk, Solna, Sweden), in order to obtain
a depiction of resistance trends within the susceptibility
range in our population.
Susceptibility to Cefditoren was tested by agar dilution
method, according to CLSI 2011 methodology. Escheri-
chia coli ATCC 25922 was used as a quality control
microorganism and was included in each run. Cefditoren
standard powder was supplied by GlaxoSmithKline (Hel-
las). In lack of CLSI or EUCAST established breakpoints
for Cefditoren, isolates with MIC ≤ 1 mg/L were con-
sidered as sensitive according to the recent literature
[12-14]. This choice was further supported by the recent
EUCAST clinical breakpoints for third generation cepha-
losporins against Enterobacteriaceae [15].
Phenotypic identification of extended-spectrum β-lac-
tamases (ESBL) production was confirmed following the
CLSI (2011) guidelines [11]. Phenotypic identification of
plasmidic AmpC β-lactamases was additionally tested
using the phenyl boronic acid inhibition method, as
described previously [16]. Other mechanisms of resist-
ance (production of inhibitor-resistant TEM [IRT] β-
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lactamases and penicillinase production or hyperproduc-
tion) were detected by phenotypic analysis and interpret-
ation following the EUCAST guidelines [15].
Definitions
Male gender, pregnancy, history of urinary tract infection
in the last two weeks, history of admission to the hospital
in the last 30 days, the presence of diabetes mellitus or
nephrolithiasis and the presence of a urinary catheter on
sampling were considered as complicating factors [10].
Female non pregnant patients, without complicating
factors, presenting with at least one urinary symptom
(i.e. frequency, dysuria, hematuria, suprapubic pain,
excluding fever and vaginal symptoms), and a positive
urine culture were assigned to the group “Acute Un-
complicated Cystitis” (AUC) [3].
Statistical analysis
In the univariate analysis proportions of NS (non sus-
ceptible) or R (resistant) strains between categorical
variables were compared using the Pearson’s chi-square
test or the Fischer’s exact test where appropriate. A p-
value <0.05 was considered as statistically significant.
Univariate predictors with p < 0.1 were tested for in-
clusion in a step-wise multivariate model. Nonsignifi-
cant variables were removed sequentially until only
those significant at p < 0.1 remained. The analysis was
carried out using Stata 10.0 (Stata Corp, Texas, USA).
Results
Demographic analysis
Cefditoren was studied against a total of 563 isolates (330
E. coli, 142 Proteus mirabilis and 91 Klebsiella spp-three
K. oxytoca and 88K. pneumoniae). Fully evaluable clin-
ical information was available for 334/563 isolates
(59.3%), i.e. 214/330 E. coli (64.8%), 75/142 P. mirabilis
(52.8%) and 45/91 Klebsiella spp (49.5%). Women
accounted for 88.3% of the patients with a mean age of
45.8 years (SD ± 18.5ys). A total of 318 cases of acute un-
complicated cystitis were available for evaluation. Demo-
graphic and clinical data are listed in detail in Table 1.
Antimicrobial susceptibility testing for the total sample
population
The in vitro activity of the antimicrobial agents tested
against all the isolates in the study are listed in detail in
Table 1 Demographic and clinical data per type of







No of patients (% of total) 172 (51.5) 334 (100)
Gender (% female) 100 88.3






15–65 141 (82.0) 248 (74.3)
>65 25 (14.0) * 70 (20.9)
Missing 7 (4.0) 16 (4.8)
History of previous UTI
in the last 2 weeks
0a 13 (3.9)
History of admission
in the last year
11 (6.4) * 39 (11.7)
History of urinary catheter
placement during admission
7 (4.1) 18 (5.4)
Diabetes mellitus 0a 30 (9.0)
Nephrolithiasis 0a 27 (8.1)
Actively having a urinary catheter 0 a 15 (4.5)
Pregnancy 0a 6 (1.8)
History of UTI in the last 3 months 16 (9.3) * 51 (15.3)
History of UTI in the past 64 (37.2) 122 (36.5)
History of receiving an antibiotic
in the last 3 months for
reason other than UTI
33 (19.2) 62 (18.6)
AUC acute uncomplicated cystitis, S.D. standard deviation,UTI urinary tract infection.
a Not applicable by protocol definition. *P ≤ 0.05.
Table 2 Non-susceptibilitya rates (%) for the total isolate
yield of the study (n = 563)







Amoxicillin 31.5 N/Α b 33.1
Amoxicillin/clavulanic acid 6.4 1.1 4.2
Cefalothin 9.1 3.3 13.4
Cefuroxime sodium 2.7 1.1 1.4
Cefuroxime axetil 3.9 3.3 2.8
Co-trimoxazole 23.6 11.0 13.4
Nalidixic acid 8.2 9.9 5.6
Ciprofloxacin 4.8 5.5 1.4
Mecillinam 3.6 1.1 22.5
Nitrofurantoin 6.4 30.8 N/Α b
Fosfomycin c 1.2 1.1 9.9
Cefotaxime 3.0 1.1 1.4
Ceftazidime 0.6 1.1 3.5
Gentamicin 2.1 1.1 4.2
Netilimicin 0.6 1.1 0.7
Amikacin 0.9 1.1 0
Piperacillin-tazobactam 0.6 1.1 0
Ticarcillin-clavulanate 0.9 1.1 0.7
Imipenem 0.6 0 0.7
Cefditoren 3.0 3.3 2.1
a CLSI 2011 breakpoints of susceptibility were applied.
b N/A: not applicable (species inherently resistant).
c Fosfomycin trometamol is no long marketed in Greece.
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Table 2, in terms of non-susceptibility rates (intermedi-
ate resistance and resistance rates). Cefditoren non-
susceptibility rates for E. coli, P. mirabilis and Klebsiella
spp were 10/330 (3%), 3/142 (2.1%), and 3/91 (3.3%) re-
spectively, while respective values for MIC50/MIC90
were 0.25/0.50, 0.125/0.25, and 0.25/0.5 mg/L (in total
0.25/0.5 mg/L, range 0.03-128 mg/L). In Figure 1, MIC
distribution for cefditoren against all isolates of E. coli,
P. mirabilis and Klebsiella spp is displayed.
Phenotypic identification of ESBL production was
evident in 9 strains (8 E coli, 1 Klebsiella spp), while
plasmid-mediated Amp-C in 3 strains (3 P. mirabilis).
Production of inhibitor-resistant TEM β-lactamases and
penicillinase production/hyperproduction was identified
in 11 strains (9 E coli, 2 Klebsiella spp). All ESBL-
producer strains were resistant to cefditoren (MIC
range 16–128 mg/L); the same applied for all three
plasmidic AmpC producers possessing MIC of cefdito-
ren at 64 mg/L. TEM/hyperproducers displayed more
variable MICs against cefditoren; in 7/11 the MIC was
equal to 1 mg/L, whereas it ranged between 2–4 mg/L
for the 4 remaining strains of this kind.
Cefditoren displayed good in vitro activity against
E. coli isolates with different mechanisms of resistance.
For ampicillin non-susceptible strains (104 strains)
cefditoren MIC50/MIC90 values were 0.25/1 mg/L,
whereas for amoxicillin-clavulanate and ciprofloxacin
non-susceptible strains (21 and 16 strains respectively)
the respective values were 0.5/128 mg/L. Finally, cef-
ditoren MIC50/MIC90 values of cotrimoxazole non-
susceptible strains (n = 78) were 0.25/4 mg/L.
Antimicrobial susceptibility testing for the study
population with available clinical data
Non-susceptibility rates for E. coli isolates from AUC
cases are listed in Table 3. MIC50/90 for cefditoren
were 0.25/0.50 mg/L for AUC E coli isolates. Non-
susceptibility rates for Proteus mirabilis and Klebsiella
spp. isolates from AUC cases are listed in Table 4;
MIC50/90 values for cefditoren were 0.125/0.25 and
0.125/0.25 mg/L respectively.
Risk factors for cefditoren non-susceptibility
In the total isolates yield (563 strains), cefditoren
non-susceptibility was positively associated with the
Figure 1 Cefditoren (%) MIC distribution per species.
Table 3 Escherichia coli non-susceptibility ratesa for cases
with available clinical data
Antimicrobial agent AUC
(n = 119)




Amoxicillin/clavulanic acid 5.0 4.7
Cefalothin 6.7 7.9
Cefuroxime sodiumb 0.8 1.4
Cefuroxime axetilc 2.5 3.3
Co-trimoxazole 18.5 18.7














AUC. acute uncomplicated cystitis; a CLSI 2011 breakpoints of susceptibility
were applied; bResults reported according to the breakpoint of parenteral
cefuroxime; c Results reported according to the breakpoint of oral cefuroxime;
d Fosfomycin trometamol is no long marketed in Greece.
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co-existence of non-susceptibility to other antimicro-
bials, with the exceptions of mecillinam, imipenem,
fosfomycin, nitrofurantoin, gentamicin and netilmicin.
Cefditoren MIC was significantly higher in nalidixic/
ciprofloxacin non-susceptible strains. The same applied
for ciprofloxacin MIC in cefditoren non-susceptible iso-
lates (Table 5). These results were also true for the
subgroup of isolates with available clinical information
(data not shown). Univariate analysis of clinical infor-
mation has demonstrated the following risk factors
associated with Cefditoren non-susceptibility: the pres-
ence of fever (P = 0.016), history of urinary tract infection
in the previous two weeks from sampling (P = 0.026),
history of urinary tract infection in the previous three
months (P = 0.012), use of a fluoroquinolone during the
previous three months (P = 0.018) and use of a cephalo-
sporin or a clavulanate fixed combination in the previous
three months (P = 0.042). In the multivariate analysis
only history of urinary tract infection in the previous two
weeks and in the previous three months retained
Table 4 Proteus mirabilis. and Klebsiella spp non-susceptibility ratesa for cases with available clinical data
Antimicrobial agent Proteus mirabilis Klebsiella spp.
AUC b (n = 31) Total cases with
available clinical
information (n = 75)
AUC b (n = 22) Total cases with
available clinical
information (n = 45)
Amoxicillin 35.5 33.3 N/A c N/A c
Amoxicillin/
clavulanic acid
6.5 5.3 0 2.2
Cefalothin 12.9 12.0 4.5 4.4
Cefuroxime
sodium
0 2.7 0 0
Cefuroxime axetil 3.2 5.3 4.5 2.2
Co-trimoxazole 16.1 16 9.1 11.1
Nalidixic acid 9.7 6.7 0* 8.9
Ciprofloxacin 6.5 2.7 0 4.4
Mecillinam 25.8 21.3 0 0
Nitrofurantoin N/A c N/A c 40.9 33.3
Fosfomycin 0 0 0 2.2
Cefotaxime 3.2 3.2 0 0
Ceftazidime 6.5 5.3 0 0
Gentamicin 0 2.7 0
Netilimicin 0 0 0 2.2
Amikacin 0 0 4.5 4.4
Piperacillin-
tazobactam
0 0 0 0
Ticarcillin-
clavulanate
0 0 0 0
Imipenem 0 0 0 0
Cefditoren 3.2 2.7 0 2.2
a CLSI 2011 breakpoints of susceptibility were applied; b Acute Uncomplicated Cystitis, c not applicable, , *P ≤ 0.05.
Table 5 MIC50/90 distribution according to different resistance phenotypes
Cefditoren susceptible strains Cefditoren non-susceptible strains P
Ciprofloxacin MIC50/MIC90 (mg/L) 0.012/0.032 0.19/32 <0.001
Nalidixic acid susceptible strains Nalidixic acid non-susceptible strains P
Cefditoren MIC50/MIC90 (mg/L) 0.25/0.5 0.25/48 <0.001
Ciprofloxacin susceptible strains Ciprofloxacin non-susceptible strains P
Cefditoren MIC50/MIC90 (mg/L) 0.25/0.5 0.5/64 <0.001
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statistical significance (Table 6). Clinical and microbio-
logical charecteristics of isolates with resistance in cefdi-
toren are listed in Table 7.
Discussion
Cefditoren is a rapidly bactericidal antibiotic as demon-
strated by previous in vitro studies [7-9]. Clinical data
on its use in urinary tract infections are currently lack-
ing whereas microbiological data against uropathogens
are scarce [13,14]. Currently there are not established
susceptibility breakpoints for cefditoren against Gram-
negative rods; for this reason we used as tentative
breakpoint of susceptibility the threshold of ≤1 mg/L,
according to recently published evidence as well as the
most recently proposed clinical breakpoints by
EUCAST, setting susceptibility of the 3rd generation
cephalosporins against Enterobacteriaceae at ≤1 mg/L
[13-15].
This is among the first studies which report antimicro-
bial susceptibility data of cefditoren in comparison to
other commonly used antimicrobials from a large
population-based surveillance study of outpatients with
UTIs. According to the data presented herein, cefditoren
had the lowest rate of resistance among the tested
orally-available antibiotics after fosfomycin- which is not
marketed in our country in the last 10 years. In vitro ac-
tivity of cefditoren in our population of uropathogens
was in accordance with data from Spain [14], whereas a
study from Korea reported higher MIC90 (16 mg/L)
compared to our data (0.5 mg/L) [13]. As reported pre-
viously, cefditoren was not active against ESBL-
producing strains [9,13], however its activity against
TEM/hyperproducers was more variable compared to
previous reports although the majority of the strains
(63.6%) were inhibited in clinically achievable concentra-
tions [9].
Resistance to cefditoren was associated in our study
with resistance to nalidixic acid- and resistance to cipro-
floxacin. These observations are in accordance with data
from Korea, a country with high levels resistance to
ciprofloxacin among uropathogens (30.3% in the study
by Ko et al.) [13]. On the other hand, no association of
resistance to cefditoren was found with mecillinam, fos-
fomycin, nitrofurantoin and aminoglycosides, indicating
that their use as first line treatment options in commu-
nity acquired UTIs as recommended by local guidelines
would not affect the susceptibility of cefditoren. This ob-
servation was also confirmed in a recent large European
multicenter study [17]. In both ECO⋅SENS studies,
resistance to any antimicrobial studied was markedly
higher in isolates resistant to any other antimicrobial,
irrespective of whether or not the antibiotics belonged
to the same class [17,18]. This has been partially attri-
buted to a pool of resistance in aminopenicillins,
folate inhibitors and fluoroquinolones among E.coli in
the community and the long established plasmid-
mediated resistance to ampicillin and to trimethoprim/
sulfamethoxazole [17].
The accompanying questionnaire enabled us to classify
UTIs as “complicated” or “uncomplicated” and to eluci-
date risk factors for resistance to cefditoren beyond the
well-recognized use of an antibiotic of the same class in
the previous 15 days-3 months [6,19,20]. The presence
of fever indicating complicated UTI, previous use of a
cephalosporin or a fixed combination of clavulanate or a
quinolone for any reason and recent history of UTI in
the last two weeks and three months were elucidated in
the univariate analysis as risk factors for cefditoren re-
sistance; however only the history of UTI retained statis-
tical significance in the multivariate analysis, with an
Odds Ratio of 39.65 for the preceding two weeks and
22.67 for the preceding two months. Cephalosporins are
not currently indicated as first line antibiotics in acute
uncomplicated cystitis, not only because other classes of
antibiotics provide more convenient schemes of treat-
ment, but also for epidemiological reasons [3,21]. How-
ever, an emerging trend of resistance in cotrimoxazole is
documented in several regions [2,6,13,14]. IDSA and
several other national guidelines advise against the em-
pirical use of cotrimoxazole in settings with known re-
sistance above the threshold of 20% [3,20,21]. In our
country, data acquired through a big population-based
surveillance revealed a resistance rate of 19.2% for AUC
E. coli strains [10]. According to these recently published
data from our group, the most potent in vitro antibiotics
available for oral use in AUC in our community were
fosfomycin, mecillinam, cefuroxime axetil, ciprofloxacin
and amoxicillin/clavulanic acid with resistance rates of
Table 6 Multivariate analysis of risk factors for cefditoren resistance
Parameter p value Odds Ratio 95% Confidence Interval
Presence of fever 0.14 5.69 0.58-55.54
History of UTI in the previous 2 weeks 0.006 39.65 2.88-546.30
History of UTI in the previous 3 months 0.04 22.67 1.12-457.48
Fluoroquinolone use in the last 3 months 0.32 0.16 0.04-5.89
Cephalosporin or clavulanate fixed combination in the last 3 months 0.86 0.78 0.05-11.48
UTI urinary tract infection.
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Table 7 Microbiological and clinical information of Cefditoren-resistant isolates








BA 356 E. coli 1 S S I R S S S S S S S S S S S S S S TEM-1 hyperproduction NA
BA 425 E. coli 1 S S S R S S S S S S S S S S S S S R TEM-1 + SXTR 75ys female AUC,
doxycycline in the
last 3mos
BC 165 E. coli 1 S S R R S S S R S S S S S S S S S S TEM-1 hyperproduction 25ys female UTI,
Hx of UTI in the
last 2wks
BC 211 E. coli 1 R S I R S S S R S S S S R S S S S R TEM-1 hyperproduction +
SXTR + cross resistance
to all fluoroquinolones
81ys female AB with
diabetes mellitus and
nephrolithiasis, Hx of
UTI in the last 2ks
and 3 mos, use of CIP
in the last 3mos
BTH 486 E. coli 1 S S I R S S S S S S S S S S S S S R TEM-1 hyperproduction + SXTR NA
BM 538 E. coli 1 S S I R S S S R S S S S S S S S S S TEM-1 hyperproduction NA
PER 41ii E. coli 1 S S S R S S S S S S S S S S S S S S TEM-1 45ys male AB, Hx of
UTI in the last year
BTH 229
Klebsiella spp
2 S S S R S S S S S S S S S S I S S R SHV-1 natural + FTR + SXTR NA





2 R S S R S S S S S S S S R S R S S R SHV-1 + FTR + SXTR +
cross resistance to all
fluoroquinolones
80ys female AB with
folley catheter, Hx of
UTI in the last 2wks
and 3mos, use of
cefaclor and TZP
in the last 3 months
BΚ 319 E. coli 4 R S I R S S S S S S S S R S S S S R TEM-1 hyperproduction +
SXTR + cross resistance
to all fluoroquinolones
18ys female AUC,
Hx of UTI in the
last 3mos
BΑ 569 E. coli 16 S S S R R S R R S S S S S S S S S R ESBL CTX-type + SXTR NA
BTH 470 E. coli 32 S S S R R S R R S S S S R S S S S S ESBL CTX-type + Resistance
quinolones NalR
40ys female AUC,
Hx of UTI in the
last year



























Table 7 Microbiological and clinical information of Cefditoren-resistant isolates (Continued)
BM 463
P. mirabilis





use of cefaclor in
the last 3 mos
BM 465
P. mirabilis
64 S S R R S S S R S S S S S S R S S S AmpC plasmidic +
natural FTR
36ys female AUC,





64 S S R R S S S R S S S S S S R S S S AmpC plasmidic + natural FTR NA




Hx of UTI in the last
3mos, use of SXT





128 S S I R R S R R S S S S S S S S S R ESBL CTX-type + SXTR NA
GEM 250
E. coli
128 R S S R R S R R S S S S R S S S S R ESBL CTX-type + SXTR +






Hx of UTI in the
last 2wks and use




128 S R S R R R R R R S S R S S R I S R ESBL + SXTR + FTR + FOSR NA
TZ 250 E. coli 128 R R R R R R R R S R R R R R R R R R MBL (XDR) + Cross resistance
to all fluoroquinolones
NA
CIP: Ciprofloxacin, AN: Amikacin, AMC: Amoxicillin / clavulanic acid, AM: Ampicillin, CTX: Cefotaxime, CAZ: Ceftazidime, CXM: Cefuroxime, CF: Cephalothin, FOS: Fosfomycin, GM: Gentamicin, IMP: Imipenem, MEC:
Mecillinam, NA: Nalidixic acid, NET: Netilmicin, FT: Nitrofurantoin, TZP: Piperacillin / tazobactam, TCC: Ticarcillin / clavulanate, SXT: Trimethoprim / sulfamethoxazole. S: Sensitive, I:Intermediate susceptibility, R:



















1.6%, 3.4%,1.7%, 2.2% and 5.2% respectively. Interest-
ingly, in this study cefditoren and oral cefuroxime dis-
played co-resistance only in isolates harboring ESBL or
MBL mechanism of resistance (Table 7), although their
overall susceptibility rates in the studied population were
comparable (97.1% versus 94.1% respectively). Currently
available data do not permit to adopt for cefuroxime the
same risk factors elucidated for cefditoren but it is im-
portant to note that compared to other countries, cepha-
losporins of 2nd and 3rd generation and amoxicillin/
clavulanic acid retain susceptibility among common uro-
pathogens in UTIs in our community [2,10,17,18]. As
mentioned above, fosfomycin trometamol is no longer
available in the Greek market. On the other side, col-
lateral damage with the use of quinolones as well an
alarming percentage of first step mutants among uro-
pathogens in both uncomplicated (6%) and complicated
infections (12.7%) [10] has prompted severe restriction
policies against their indiscriminate use in the Greek
community; this is also true in many countries [22,23].
Furthermore the between the ECO⋅SENS I (1999–2000)
and ECO⋅SENS II (2007–2008) studies ciprofloxacin
resistance almost doubled in Greece [17,18], mandating
quinolone sparing policies in our community.
A certain weakness of this study is the lack of clinical
data for almost one third of the studied isolates. How-
ever the lack of significant differences in resistance rates
against all antibiotics tested between the populations
with and without clinical information, as well as the
large and representative sample of our study argues in
favor of an extended applicability of the conclusions in
our community. Furthermore the addition of a pool of
isolates without clinical data allowed for a simulation of
real life treatment scenario of an outpatient with UTI.
Another possible weakness is the lack of clinical thera-
peutic data, which would enable us to detect therapeutic
failure in the community with currently used agents, but
this was beyond the design and the scope of the current
study.
Certainly no strong argument exists for the use of cef-
ditoren as first line option in acute uncomplicated UTIs
since other treatment options mentioned above retain
good activity. However many UTIs treated in the com-
munity setting are not episodes of acute uncomplicated
cystitis mandating concentrations in the upper urinary
tract; patients are often pretreated with other first-line
classes of antibiotics; apart from recent antibiotic use
patients with complicated urinary tract infections treated
as outpatients frequently bear risk factors for resistance
to multiple classes of antibiotics [3,20]. Cefditoren could
represent a treatment option in several cases among the
above-mentioned patient/risk groups. According to our
results, cefditoren could also be used in our community
as a switch to oral treatment of patients with UTIs and
risk factors for resistance to 1st line options, initially
treated with a parenteral antibiotic. A strong argument
for the selection of cefditoren could be the lack of cross-
resistance with aminoglycosides, mecillinam, nitrofuran-
toin and fosfomycin.
Conclusions
In summary, cefditoren was the most potent in vitro
antibiotic available for oral use in our country, against
all three major pathogens causing UTIs in the outpatient
setting. A potential was demonstrated for its use as em-
pirical treatment in outpatients with no recent history of
UTI, as an alternative to first line antimicrobials or in
patients with risk factors for resistance to currently indi-
cated first treatment options. Clinical studies are war-
ranted to clearly define its possible role in the treatment
of UTIs in outpatients.
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